Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Crizotinib.

David F Heigener1, Martin Reck2

  • 1Department of Thoracic Oncology, LungenClinic Grosshansdorf, Grosshansdorf, Germany. D.heigener@lungenclinic.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same author

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Clinical lung cancer·2026
Same author

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC.

American journal of respiratory and critical care medicine·2026
Same author

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition.

Cell metabolism·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Crizotinib shows high effectiveness in non-small-cell lung cancer (NSCLC) with specific ALK, ROS1, or MET mutations. Molecular typing is crucial for identifying patients who will benefit from this targeted therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-small-cell lung cancer (NSCLC) harbors specific genetic alterations, including EML4-ALK rearrangements, ROS1 rearrangements, and MET Exon 4 skipping mutations.
  • These alterations lead to constitutive activation of receptor tyrosine kinases (RTKs), driving tumor growth.
  • Crizotinib targets these activated RTKs, offering a personalized treatment approach.

Purpose of the Study:

  • To evaluate the efficacy of crizotinib in NSCLC patients with specific molecular alterations.
  • To highlight the importance of molecular diagnostics in NSCLC treatment selection.
  • To review the known toxicities associated with crizotinib therapy.

Main Methods:

  • Utilized immunohistochemistry (IHC) to detect ALK-protein expression as a predictive biomarker.
Keywords:
ALK-RearrangementC-METCrizotinibROS-1

Related Experiment Videos

  • Employed fluorescence in situ hybridization (FISH) for detecting ALK and ROS1 rearrangements.
  • Applied sequencing methods to identify MET mutations.

    • Main Results:

    • Crizotinib demonstrates robust effectiveness in NSCLC with EML4-ALK rearrangements (3-5% of NSCLC), yielding impressive response rates.
    • Significant efficacy is also observed in patients with ROS1 rearrangements (approx. 1% of NSCLC).
    • Crizotinib shows efficacy in a subset of patients with MET Exon 4 skipping mutations (approx. 3% of NSCLC).

    Conclusions:

    • Crizotinib is a highly effective targeted therapy for NSCLC harboring ALK, ROS1, or MET mutations.
    • Molecular typing of NSCLC is essential for identifying patients who can benefit from targeted treatments like crizotinib.
    • Crizotinib expands the landscape of molecularly targeted therapies beyond EGFR inhibitors in NSCLC.